newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society

  • AEON Biopharma presented new analytical & functional data supporting biosimilarity of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society held June 4-7, 2026, in Orlando, Florida.
  • Chad K. Oh, M.D., AEON's Chief Medical Officer, presented the poster detailing evidence that ABP-450 demonstrates highly similar biological activity to BOTOX® across multiple orthogonal approaches.
  • LC-MS peptide mapping showed 93%-99% sequence coverage across the core neurotoxin & accessory proteins with no variant peptides observed between the two products.
  • All ABP-450 lots passed the LD 50 potency assay within predefined equivalence criteria established from BOTOX® reference results, reinforcing functional similarity.
  • The data builds on previously reported primary structure findings to strengthen the analytical foundation for ABP-450's full-label U.S. market entry for therapeutic indications.
  • ABP-450 is the same botulinum toxin complex approved for cosmetic use by Evolus, Inc. as Jeuveau®, manufactured by Daewoong Pharmaceutical in a facility authorized by the U.S. FDA, Health Canada, & EMA.
  • AEON holds exclusive development & distribution rights for ABP-450 in the U.S., Canada, EU, UK, & other international territories for therapeutic indications.
  • The presentation title was "Establishing Structural & Functional Comparability Between ABP-450 and OnabotulinumtoxinA to Support Biosimilarity" (abstract #: 2349958).
  • BOTOX® remains the only botulinum toxin therapy currently approved for chronic migraine, the largest therapeutic indication for botulinum toxin.